Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine | Zendy

Abhishek Basu | Zendy; Prosenjit Ghosh | Zendy; Arin Bhattacharjee | Zendy; Arup Ranjan Patra | Zendy; Sudin Bhattacharya | Zendy

Open Access

Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine

Author(s) -

Abhishek Basu,

Prosenjit Ghosh,

Arin Bhattacharjee,

Arup Ranjan Patra,

Sudin Bhattacharya

Publication year - 2015

Publication title -

mutagenesis

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.723

H-Index - 91

eISSN - 1464-3804

pISSN - 0267-8357

DOI - 10.1093/mutage/gev011

Subject(s) - genotoxicity , cisplatin , micronucleus test , bone marrow , pharmacology , apoptosis , chemistry , chemotherapy , cancer research , clastogen , micronucleus , mitomycin c , oxidative stress , toxicity , medicine , immunology , biochemistry , biology , genetics , organic chemistry

Cisplatin (CDDP) is one of the first-line anticancer drugs indicated for use against various form of human malignancies; but, the therapeutic outcome of CDDP chemotherapy is limited due to the development of myelosuppression and genotoxicity which may lead to secondary cancer. Induction of oxidative stress in normal host cells is thought to be responsible for these adverse effects. Therefore, in search of a potential chemoprotectant, an oraganovanadium compound, viz., vanadium(III)-l-cysteine (VC-III) was evaluated against CDDP-induced clastogenicity and cytotoxicity in bone marrow cells of Swiss albino mice. CDDP was administered intraperitoneally (5mg/kg body weight [b.w.]) and VC-III was given by oral gavage (1mg/kg b.w.) in concomitant and pretreatment schedule. The results showed that VC-III administration significantly (P < 0.001) enhanced cell proliferation and inhibited apoptosis in the bone marrow niche indicating recovery of CDDP-induced myelosuppression. VC-III also significantly (P < 0.001) decreased the percentage of chromosomal aberrations, the frequency of micronuclei formation and the extent of DNA damage. The observed antigenotoxic and cytoprotective effect of VC-III was attributed to its attenuation of free radicals status and restoration of oxidised and reduced glutathione levels. These results suggest that VC-III is a potential candidate for future development as a chemoprotective agent against chemotherapy-associated primary and secondary complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research